Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSSAMER BIO, INC. (GOSS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On February 23, 2026, Gossamer disclosed that results for its Phase 3 PROSERA study of seralutinib for the treatment of pulmonary arterial hypertension had failed to meet the primary endpoint, citing patients at Latin American sites performing particularly well on placebo due to enrollment of a heavily-treated lower-risk population.

On this news, Gossamer’s stock price fell $1.71, or 80.3%, to close at $0.42 per share on February 23, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Gossamer securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com.
Email us at: [e-mail]
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.